Melanoma CoE News

2020

  • A research team, led by Keiran Smalley, Ph.D., director of the Donald A. Adam Melanoma and Skin Cancer Center of Excellence and Peter Forsyth, M.D., Chair of the Department of Neuro-Oncology, hypothesized that the cerebrospinal fluid of LMM patients could impact melanoma cells by modulating their molecular profile. They confirmed this hypothesis by incubating cerebrospinal fluid from the LMM patients with melanoma cells and discovered that the fluid was able to induce activation of proteins and signaling pathways involved in malignant progression, including the PI3K/AKT pathway, integrins, B cell signaling, mitotic cell cycle progression, TNFR, TGF-β and oxidative stress. Full story

2019

  • In a new study published in EBioMedicine, researchers with Moffitt Cancer Center’s Donald A. Adam Melanoma and Skin Cancer Center of Excellence reveal that differences at the single-cell level can predict responses to initial BRAF inhibitor therapy, and that leveraging these differences may improve patient outcomes. Full Story
  • Using a combination of novel genetic tools, the Tsai and Brown labs are studying how clones of keratinocytes exposed to UV radiation expand and contract over time, forming the basis for skin cancer. Full Story
  • Researchers have discovered a mechanism by which melanoma cells become resistant to the commonly used drugs that target the BRAF protein and its signaling pathway. Full Story
  • Researchers in the Melanoma and Skin Cancer Center of Excellence have discovered a signaling pathway between cytokines and BRAF that promotes tumor growth. Full Story
  • Researchers in the Melanoma and Skin Cancer Center of Excellence are working to change the prognosis for patients with metastatic uveal melanoma. They have identified a new drug combination that is effective against metastatic uveal melanoma cells in preclinical studies. Their findings were published in Clinical Cancer Research. Full story